January 23, 2018, Moscow – Association of International Pharmaceutical Manufacturers (AIPM) announces that Vadim Vlasov, President of the Novartis Group Russia, Regional Director of Novartis for Eastern and Central Europe and the CIS, was elected to the position of Chairman of the AIPM Board of Directors.
In strict accordance with the AIPM Statutes, the Chairman of the AIPM Board of Directors is elected by the Board of Directors for a two-year period with the possibility of once re-election.
Since January 23, 2014, Naira Adamyan, General Manager Rx Eurasia, Sanofi, has been the Chairman of the AIPM Board of Directors during 4 years. Now she will continue to serve as AIPM Board of Directors member.
“I would like to thank AIPM as whole and Mr. Shipkov in person for a very productive work and partnership we have had for the benefit of patients in Russia over past 4 years. I hope, these years contributed a lot into building of the modern pharma industry in our country, and Association always stayed at the forefront of all the changes coming the industry’s way, being a symbol of professionalism, compliance and reliability. I’m proud to convey the chairmanship to Mr. Vlasov and I’m sure that he will successfully continue our efforts both in the area of working on the industry’s hottest topics and on the way of further strengthening of the responsible and compliant pharma industry in Russia”, said Naira Adamyan, General Manager Rx Eurasia, Sanofi, member of the AIPM Board of Directors.
“For almost a quarter of a century, AIPM has played the role of the voice of the international pharmaceutical industry and reliable partner in the dialogue on the most actual topics for the healthcare system in Russia. We will continue to systematically and consistently implement joint goals to find and introduce ways to develop the system and improve efficiency through, inter alia, best international practices. I hope that our proposals will be supported by the state, which allows the pharmaceutical industry in our country to reach a new level and increase the competitiveness of the industry as a whole. And Russian patients will first benefit from this,” noted Vadim Vlasov, President of the Novartis Group Russia, Regional Director of Novartis for Eastern and Central Europe and the CIS, Chairman of the AIPM Board of Directors.
“AIPM expresses deep gratitude to Naira Adamyan for her effective and highly professional leadership of the Association for 4 years in the difficult period for the development of the pharmaceutical industry and the healthcare system, as well as for the consistent service of the AIPM mission for improving the quality of medical care and expanding of medicines’ assortment. Following the provisions of the AIPM Statutes, the regular rotation of Chairman of the AIPM Board of Directors has happened and we welcome Vadim Vlasov, who previously held the position of Vice-Chairman of the AIPM Board of Directors, as the newly elected Chairman of the AIPM Board of Directors. I am confident that with the new Chairman of the Board of Directors, continuity and adherence to the Association’s professional priorities for increasing the availability of modern medicines provision for the population of our country will be preserved,” emphasized Vladimir Shipkov, AIPM Executive Director.
The Association of International Pharmaceutical Manufacturers (AIPM) was established in 1994 and represents on the territory of the Russian Federation the leading international pharmaceutical companies – manufacturers and developers of modern effective, safe and high‑quality medicines. AIPM brings together 60 international companies, which account for over 80% of world pharmaceutical production and more than 60% of the volume of medicines supplied to the Russian Federation.
For additional information, please contact
Legal and Communications Director, AIPM
+7 (495) 933 70 40,
Version for printing